UCT-01-097 / 1200 Pharma - LARVOL DELTA

UCT01097-001: First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=32 | Terminated | Sponsor: 1200 Pharma, LLC | N=106 ➔ 32 | Trial completion date: Aug 2024 ➔ Feb 2024 | Recruiting ➔ Terminated | Trial primary completion date: Sep 2023 ➔ Feb 2024; Stopped for strategic business reasons. The decision to stop the study was not connected to any safety concerns, or new risk associated with the study product, intervention, or procedures.

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor

Development of UCT-01-097, a novel orally available ERK1/2 inhibitor for the treatment of ERK1/2 dependent cancers (AACR 2023) - P1 | "We evaluated multiple preclinical and clinically staged ERK1/2 inhibitors—including ERAS-007 and BVD-523—in a 500+ cell line screening platform and identified cancers with subpopulations that are sensitive to this class of inhibitor. Inhibition of xenograft tumor growth was achieved using both daily dosing and intermittent dosing schedules. We have successfully submitted a regulatory IND and are currently enrolling a Phase 1 clinical trial in advanced solid tumors for treatment with UCT-01-097 (NCT04761601)."

Oncology • Solid Tumor • BRAF • KRAS • MAP2K1